NASDAQ:BIVI BioVie Q1 2027 Earnings Results & Report $1.34 +0.04 (+2.69%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more. BioVie reported Q1 2027 earnings on November 6, 2026. The company reported EPS of -$0.68. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateNovember 6, 2026TimeAfter Market ClosesConference Call7:00 AM ET BioVie EPS ResultsActual EPS-$0.68Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersBioVie Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) BioVie Q1 2027 Earnings FAQ Did BioVie beat earnings estimates for Q1 2027? BioVie (NASDAQ:BIVI) reported earnings of -$0.68 per share for Q1 2027. The report was announced on Friday, November 6, 2026. BioVie Earnings HeadlinesBioVie Reports Distinct Biomarker Responses In Phase 2 Long COVID Trial; Stock DownNovember 9 at 2:54 PM | rttnews.comBioVie identifies two Long COVID patient groups with distinct responses to bezisterimNovember 9 at 2:54 PM | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 10 at 1:00 AM | Behind the Markets (Ad)BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual WorkshopNovember 9 at 8:00 AM | globenewswire.comBioVie Announces $4.74 Mln Registered Direct Offering; Shares Fall 26%November 4, 2026 | rttnews.comBioVie to raise $4.74 million in registered direct offeringNovember 4, 2026 | finance.yahoo.comSee More BioVie Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email. Email Address About BioVieBioVie (NASDAQ:BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological, neurodegenerative and inflammatory diseases. Its research programs are aimed at addressing disease mechanisms such as chronic inflammation, insulin resistance and impaired cellular signaling. The company's lead investigational product, bezisterim (also known as NE3107), is an orally administered, blood-brain barrier-penetrating small molecule being studied for potential use in disorders including Alzheimer's disease and Parkinson's disease. BioVie has also developed BIV201, an investigational continuous-infusion formulation of terlipressin intended to treat refractory ascites associated with advanced liver cirrhosis. BioVie conducts clinical development activities primarily in the United States and works with research institutions and clinical investigators to evaluate its product candidates. The company is headquartered in Carson City, Nevada, and is led by President and Chief Executive Officer Cuong Do.View BioVie ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
